As a result, the first generation of HER inhibitors, namely anti-HER2 mAb trastuzumab (1988), anti-EGFR mAbs cetuximab (2004) and panitumumab (2006), and EGFR TKIs gefitinib (2003) and erlotinib (2004), were developed and approved for treatment of patients with breast, colorectal, and non-small cell lung cancer, respectively [25,26,27,28]. Here, ERBB2 is linked to non-small cell lung carcinoma.